trastuzumab - Robuta Search

https://www.enhertuhcp.com/en ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Official HCP Site Discover ENHERTU, an FDA-approved treatment option. See Prescribing Information, including Boxed WARNINGS. trastuzumab deruxtecan fam official hcp site https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-enhertu-fam-trastuzumab-deruxtecan-nxki-unresectable-or FDA D.I.S.C.O. Burst Edition: FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for... Listen to a soundcast of the April 5, 2024, FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-positive solid tumors. https://scholars.duke.edu/publication/1405800 Scholars@Duke publication: Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9a94f5b2-b84e-4987-8ea1-c4346db5a5fa DailyMed - KANJINTI- trastuzumab-anns injection, powder, lyophilized, for solution dailymed trastuzumab anns injection powder https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-effect-having-trastuzumab-or-lapatinib-before-surgery-early-breast-cancer-ephos-b Cancer Research UK | A trial looking at the effect of having trastuzumab or lapatinib before... This trial was for people whose breast cancer had tested positive for the HER2 protein. This is HER2 positive breast cancer. https://pubmed.ncbi.nlm.nih.gov/24905295/ Trastuzumab-induced cardiomyopathy: incidence and associated risk factors in an inner-city... Decreased LVEF while undergoing trastuzumab therapy occurs frequently and is usually reversible. African Americans had a higher risk of developing decreased... https://boris-portal.unibe.ch/entities/publication/621a2804-e410-4bfb-840c-dd18a048d631 Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer... BACKGROUND HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast... pembrolizumab plus trastuzumab resistant advanced https://scholars.duke.edu/publication/1407161 Scholars@Duke publication: Impact of lapatinib plus trastuzumab versus single-agent lapatinib on... publication impact https://pubmed.ncbi.nlm.nih.gov/29113393/ Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in... resource utilization cost saving https://pubmed.ncbi.nlm.nih.gov/24075779/ Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in... In 2009 a prospective, randomized Phase II trial (NCT00842998) was initiated to evaluate the activity of HER2-targeting agents without chemotherapy (CT) in... https://id.wikibooks.org/wiki/Informasi_Obat/Trastuzumab Informasi Obat/Trastuzumab - Wikibuku bahasa Indonesia informasi obat trastuzumab wikibuku bahasa indonesia https://www.leafpharma.in/ Trader - Retailer of HIV Medicines & Trastuzumab Injections by Leaf Pharma, Surat hiv medicines trader retailer https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/2313/phase-iiiii-study-paclitaxelcarboplatin/?qd=38863223 A phase II/III Study of Paclitaxel/Carboplatin alone or Combined with either Trastuzumab and... New life-saving treatments for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma in clinical trial on A phase II/III Study of Paclitaxel/Carboplatin... https://essay.utwente.nl/essays/99830 Cardioprotective drugs to inhibit DOXO-induced cardiotoxicity in combination with trastuzumab for... Drug treatments, like anthracyclines with Trastuzumab for Her2-positive breast cancer, face withdrawal of promising treatments caused by the major side effect,... https://pubmed.ncbi.nlm.nih.gov/22123186/ Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast... Combined L + T treatment provides a more complete and stable inhibition of the HER network. With sustained HER2 inhibition, ER functions as a key... https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-atezolizumab-and-trastuzumab-emtansine-for-breast-cancer-astefania A trial of atezolizumab and trastuzumab emtansine for breast cancer (ASTEFANIA) This trial is looking at atezolizumab with trastuzumab emtansine after surgery to remove breast cancer. breast cancer trial atezolizumab https://www.cancer.gov/publications/dictionaries/cancer-drug/def/trastuzumab-deruxtecan Definition of fam-trastuzumab deruxtecan-nxki - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... definition of trastuzumab deruxtecan fam nci drug https://my.clevelandclinic.org/health/drugs/20579-ado-trastuzumab-emtansine-for-injection Trastuzumab Emtansine Injection: Uses & Side Effects Trastuzumab emtansine treats breast cancer. This type of cancer happens when cells in your breast grow and divide in an uncontrolled way. trastuzumab injection uses side effects https://pmc.ncbi.nlm.nih.gov/articles/PMC8039027/ Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications... Trastuzumab is a biologic therapy indicated for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer and metastatic gastric... intravenous subcutaneous formulations trastuzumab biosimilars https://experts.arizona.edu/en/publications/advanced-desmoplastic-small-round-cell-tumor-near-complete-respon/ Advanced desmoplastic small round cell tumor: Near complete response with trastuzumab-based... cell tumor https://publications-cnrc.canada.ca/eng/view/object/?id=82fe716e-772b-43db-a43b-222c4ebe525f Coiled-coil-based biofunctionalization of 100 nm gold nanoparticles with the trastuzumab antibody... Coiled-coil-based biofunctionalization of 100 nm gold nanoparticles with the trastuzumab antibody for the detection of HER2-positive cancer cells https://pubmed.ncbi.nlm.nih.gov/36300423/ Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain... Early monitoring of how well participants respond to treatment by FDG-PET scan seems to identify participants with operable HER2-positive breast cancer who... https://bibliographie.uni-tuebingen.de/xmlui/handle/10900/134122 De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in... https://experts.colorado.edu/display/pubid_253858 Conjugation of Emtansine Onto Trastuzumab Promotes Aggregation of the Antibody-Drug Conjugate by... https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT02614794&r=1 A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With... a study https://scholars.duke.edu/publication/760981 Scholars@Duke publication: Clinical efficacy of taxane-trastuzumab combination regimens for... clinical efficacy scholars duke publication https://ub01.uni-tuebingen.de/xmlui/handle/10900/153015 Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for... https://pubmed.ncbi.nlm.nih.gov/22154153/?dopt=Abstract Trastuzumab treatment in multiple lines: current data and future directions Trastuzumab improves response rate, time to progression, and overall survival when combined with first-line chemotherapy in patients with human epidermal... multiple lines current data trastuzumab treatment future https://www.health.pitt.edu/news/trastuzumab-emtansine-improves-long-term-survival-her2-breast-cancer/ Trastuzumab Emtansine Improves Long-Term Survival in HER2 Breast Cancer - Health Sciences |... Apr 9, 2026 - The findings, published Jan. 15 in the New England Journal of Medicine (NEJM), provide long-term evidence that T-DM1 is an effective adjuvant treatment for... long term https://academiccommons.columbia.edu/doi/10.7916/3rfz-1517 Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients... Abstract Background While trastuzumab has been shown to improve disease-free and overall survival in patients with HER2-positive breast cancer, it may also... predictors trastuzumab induced cardiotoxicity https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae71c003-883a-4cd8-ad50-e8cc9a54e971 DailyMed - HERZUMA- trastuzumab kit HERZUMA- trastuzumab injection, powder, lyophilized, for... dailymed trastuzumab kit injection powder https://experts.mcmaster.ca/scholarly-works/194983 Lapatinib or Trastuzumab Plus Taxane Therapy for... Learn about the scholarly work entitled Lapatinib or Trastuzumab Plus Taxane Therapy for... lapatinib trastuzumab plus therapy https://www.cochrane.org/evidence/CD006242_efficacy-and-safety-trastuzumab-metastatic-breast-cancer Efficacy and safety of trastuzumab in metastatic breast cancer | Cochrane efficacy and safety metastatic breast cancer trastuzumab cochrane https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0275321 The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: A piggy-back... Background Trastuzumab is a valuable therapy option for women with ERBB2(HER2)+ breast cancer tumours, often used in combination with chemotherapy and... https://data.mendeley.com/datasets/t3yb6fy69b/4 The benefits of trastuzumab in the treatment of HER2+ breast cancer as a function of exposure time... Dataset for the paper "The benefits of trastuzumab in the treatment of HER2+ breast cancer as a function of exposure time", DOI: 10.3332/ecancer.2022.1347 https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-trastuzumab-deruxtecan-for-cancers-that-have-a-large-amount-of-her2-destiny-pantumour02 A trial of trastuzumab deruxtecan for cancers that have a large amount of HER2 (DESTINY-PanTumour02) This trial was looking at trastuzumab deruxtecan for cancers that had a high number of HER2 receptors (HER2). https://scholars.duke.edu/publication/760955 Scholars@Duke publication: Overall survival benefit with lapatinib in combination with trastuzumab... overall survival scholars duke publication https://legalblogs.wolterskluwer.com/patent-blog/trastuzumab-x-recombinant-human-hyaluronidase-the-french-supreme-court-clarifies-the-interpretation-of-article-1-b-of-the-spc-regulation/ Trastuzumab x recombinant human hyaluronidase: the French Supreme Court clarifies the... the french supreme court trastuzumab x recombinant https://www.news-medical.net/news/2007/07/09/27230.aspx Trastuzumab and chemo improves survival in women with operable HER-2 positive breast cancer Jul 9, 2007 - A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves... https://pubmed.ncbi.nlm.nih.gov/16495393/?dopt=Abstract Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer Adjuvant treatment with docetaxel, as compared with vinorelbine, improves recurrence-free survival in women with early breast cancer. A short course of... adjuvant docetaxel vinorelbine without trastuzumab https://adisinsight.springer.com/drugsafety/803873983?error=cookies_not_supported&code=04f0d51b-2109-4276-b996-04975e487ec2 Pertuzumab/trastuzumab - AdisInsight A 42-year-old woman developed saroid-like reaction during treatment with trastuzumab and pertuzumab for triple positive breast cancer [routes, dosages, pertuzumab trastuzumab adisinsight https://adisinsight.springer.com/drugsafety/803396543?error=cookies_not_supported&code=5c881ef6-b5f0-46cc-a028-f0020cf09ff5 Capecitabine/cisplatin/trastuzumab - AdisInsight An 82-year-old man developed neutropenia, cardiotoxicity and exacerbation of hand-foot syndrome during treatment with cisplatin, trastuzumab or capecitabine for capecitabine cisplatin trastuzumab adisinsight https://liu.diva-portal.org/smash/record.jsf?pid=diva2:1382387 Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected... efficacy and safety https://prevention.cancer.gov/clinical-trials/clinical-trials-search/nct03879629 Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce... breast cancer treating patients https://pubmed.ncbi.nlm.nih.gov/17374151/ Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial Although lower than in initial studies, activity of 3-weekly trastuzumab plus vinorelbine fell within the range of results reported with weekly schedules.... https://www.enhertu.com/ ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Official Patient Website Learn more about ENHERTU® (fam-trastuzumab deruxtecan-nxki) for several types of cancer. See Full Safety and Boxed WARNINGS for more information. trastuzumab deruxtecan fam official patient https://pubmed.ncbi.nlm.nih.gov/30219886/ Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of... EUDRACT number: 2007-004326-25; NCI ClinicalTrials.gov number: NCT00629278. https://nrc-publications.canada.ca/eng/view/object/?id=82fe716e-772b-43db-a43b-222c4ebe525f Coiled-coil-based biofunctionalization of 100 nm gold nanoparticles with the trastuzumab antibody... Coiled-coil-based biofunctionalization of 100 nm gold nanoparticles with the trastuzumab antibody for the detection of HER2-positive cancer cells https://pubmed.ncbi.nlm.nih.gov/18317582/?dopt=Abstract Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab... Trastuzumab has been shown to be an effective therapy for women with breast cancer that overexpresses the human epidermal growth factor receptor 2 (her2)... cardiac management of the adjuvant trastuzumab therapy https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-rilvegostomig-trastuzumab-deruxtecan-advanced-stomach-gastro-oesophageal-junction-cancer-artemide-gastric-01 A trial looking at rilvegostomig and trastuzumab deruxtecan for advanced stomach or gastro... This trial is looking at rilvegostomig and trastuzumab deruxtecan for cancer that has spread. https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-comparing-6-months-and-12-months-of-trastuzumab-for-early-breast-cancer A trial comparing 6 months and 12 months of trastuzumab (Herceptin) for early breast cancer... This trial is looking at whether women with early breast cancer can safely have trastuzumab (Herceptin) for 6 months instead of 12. https://pubmed.ncbi.nlm.nih.gov/15536075/ A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen... Trastuzumab, a humanized antibody to HER-2, has been shown to be effective in the treatment of breast cancer in which HER-2 overexpression and metastasis... https://researchconnect.buffalo.edu/en/publications/phase-ii-trial-of-trastuzumab-in-combination-with-cytotoxic-chemo/ Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of... phase ii https://digital.library.adelaide.edu.au/items/2b87309f-de54-4e9e-9f7a-22474cb82795 Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma Trastuzumab is a therapeutic monoclonal antibody against the Her2 oncoprotein, which is over-expressed in approximately 30% of breast cancers, and is now used... https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-trastuzumab-pertuzumab-for-her2-positive-breast-cancer-aphinity A trial looking at trastuzumab and pertuzumab for HER2 positive breast cancer - APHINITY This trial is looking at adding a new drug called pertuzumab to trastuzumab for people who have had surgery for breast cancer. https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-trastuzumab-pamirtecan-pumitamig-breast-cancer-spread Cancer Research UK | A trial looking at trastuzumab pamirtecan and pumitamig for breast cancer that... This trial is looking at trastuzumab pamirtecan and pumitamig for breast cancer that has spread and cannot be removed by surgery. cancer research uk https://www.mayoclinic.org/drugs-supplements/trastuzumab-dttb-intravenous-route/description/drg-20455949 Trastuzumab-dttb (intravenous route) - Side effects & uses - Mayo Clinic side effects trastuzumab dttb intravenous route https://uwspace.uwaterloo.ca/items/addd7b8d-a294-4e7c-b3b5-f26a52118954 Effects of Trastuzumab on Alternative Splicing in HER2+ BT474 Breast Cancer Cells Alternative splicing (AS) is a fundamental process that enhances transcriptomic diversity and protein isoform complexity in eukaryotic cells. Deregulation of... https://ce.massmed.nejm.org/nejm-weekly-cme/content/tucatinib-trastuzumab-and-capecitabine-her2-positive-metastatic-breast-cancer Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer | MMS/NEJM... metastatic breast cancer https://pmc.ncbi.nlm.nih.gov/articles/PMC5718359/ Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast... Treatment with trastuzumab is a cornerstone of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer treatment, but carries an... diagnosis and treatment https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2 FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic... On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult... https://adisinsight.springer.com/drugsafety/803110150?error=cookies_not_supported&code=4a4c4d8f-0b01-4b4f-a6e1-a831e9cdf85b Carboplatin/docetaxel/trastuzumab - AdisInsight A 55-year-old woman developed trouble multitasking and feeling mentally foggy during treatment with carboplatin, docetaxel and trastuzumab [Herceptin] for carboplatin docetaxel trastuzumab adisinsight https://pubmed.ncbi.nlm.nih.gov/22689807/ Overall survival benefit with lapatinib in combination with trastuzumab for patients with human... These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients... overall survival for patients benefit lapatinib https://bibliographie.uni-tuebingen.de/xmlui/handle/10900/153015 Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for... https://scholars.duke.edu/publication/760969 Scholars@Duke publication: Randomized study of Lapatinib alone or in combination with trastuzumab... https://pubmed.ncbi.nlm.nih.gov/31881136/ Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer metastatic breast tucatinib trastuzumab capecitabine positive https://pubmed.ncbi.nlm.nih.gov/26595802/ Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition Recent clinical data indicate a synergistic therapeutic effect between trastuzumab and taxanes in neoadjuvantly treated HER2-positive breast cancer (BC)... https://adisinsight.springer.com/drugs/800087179?error=cookies_not_supported&code=bff0648c-a307-470a-abe3-12171893e7b3 Pertuzumab/trastuzumab biosimilar - Shanghai Henlius Biotech - AdisInsight A biosmilar of the fixed dose combination of Pertuzumab and Trastuzumab [See Adisinsight 800051349] designated as 'HLX319' is being developed by Shanghai shanghai henlius pertuzumab trastuzumab biosimilar biotech https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-09124 Datopotamab Deruxtecan and Trastuzumab Deruxtecan for the Treatment of HER2-Negative Unresectable,... Datopotamab Deruxtecan and Trastuzumab Deruxtecan for the Treatment of HER2-Negative Unresectable, Locally Advanced or Metastatic Breast Cancer datopotamab deruxtecan for the trastuzumab https://pmc.ncbi.nlm.nih.gov/articles/PMC10561652/ Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer - PMC Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of... advanced breast cancer trastuzumab deruxtecan previously treated https://hspop.uw.edu/publication/risk-of-heart-failure-in-breast-cancer-patients-after-anthracycline-and-trastuzumab-treatment-a-retrospective-cohort-study/ Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a... Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ,... https://pubmed.ncbi.nlm.nih.gov/33659980/ Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening... IA NEO100 facilitates brain tumor entry of trastuzumab and T-DM1 and significantly enhances their therapeutic efficacy, along with increased antibody-dependent... https://eprints.ncl.ac.uk/263030 A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with... https://researchfestival.nih.gov/2015/posters/trastuzumab-not-pertuzumab-inhibits-autophagy-and-enhances-ros-production Trastuzumab, but not pertuzumab, inhibits autophagy and enhances ROS production in human... https://pubmed.ncbi.nlm.nih.gov/25678799/ Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive... Brain metastases (BMs) represent a major issue in clinical practice and are associated with a significant worsening of patient's quality of life and, often, a... https://pubmed.ncbi.nlm.nih.gov/38995291/ HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab:... HER2DX predicts pCR in the context of neoadjuvant HP-based therapy, regardless of chemotherapy addition, and might identify patients at higher risk of... https://www.cancer.gov/about-cancer/treatment/drugs/pertuzumabtrastuzumabandhyaluronidase-zzxf Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf - NCI This targeted therapy combination consists of two monoclonal antibodies, pertuzumab and trastuzumab, and hyaluronidase-zzxf, a recombinant form of a naturally... pertuzumab trastuzumab hyaluronidase nci https://pubmed.ncbi.nlm.nih.gov/21991949/?dopt=Abstract Adjuvant trastuzumab in HER2-positive breast cancer The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer. The... adjuvant trastuzumab positive breast cancer https://www.cancer.gov/news-events/cancer-currents-blog/2017/trastuzumab-emtansine-breast-cancer Trastuzumab Emtansine for HER2-Positive Breast Cancer - NCI An NCI Cancer Currents blog on results from the TH3RESA and EMILIA clinical trials showing trastuzumab emtansine (T-DM1) improved overall survival in patients... breast cancer trastuzumab positive nci https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-trastuzumab-emtansine-pertuzumab-breast-cancer-kaitlin A trial looking at trastuzumab emtansine and pertuzumab for breast cancer (KAITLIN) This trial is looking at drug called trastuzumab emtansine alongside pertuzumab for breast cancer. looking at https://researchconnect.buffalo.edu/en/publications/potential-and-pitfalls-of-sup89supzr-immuno-pet-to-assess-target-/ Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an... https://tobias-lib.ub.uni-tuebingen.de/xmlui/handle/10900/171433?show=full Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in... chemotherapy free pembrolizumab combined trastuzumab https://pubmed.ncbi.nlm.nih.gov/41835339/ Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer:... In this large national real-world cohort from an LMIC, T-DXd demonstrated robust antitumor activity and a manageable safety profile in patients with HER2+ mBC.... https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.877825/full Frontiers | Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab... Background: Dual-targeted therapy is the standard treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and effective biomark... frontiers predicting pathological complete response https://open.library.emory.edu/concern/publications/0d9631e9-ddd6-4a32-8f2d-714b4c30548f Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance | OpenEmory Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance https://adisinsight.springer.com/drugsafety/803091394?error=cookies_not_supported&code=02d4edef-5845-4dfc-91be-c94ff8f33626 Trastuzumab - AdisInsight A 39-year-old woman with breast cancer developed dermatomyositis during treatment with trastuzumab [route and dosage not stated].The woman received three trastuzumab adisinsight https://pubmed.ncbi.nlm.nih.gov/16236737/?dopt=Abstract Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.... trastuzumab adjuvant chemotherapy positive breast https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-trastuzumab-deruxtecan-for-breast-cancer-destiny-breast07 A study looking at trastuzumab deruxtecan for breast cancer (DESTINY-breast07) This study is looking at trastuzumab deruxtecan by itself and with other cancer drugs for breast cancer. a study looking at trastuzumab deruxtecan breast cancer https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/2313/phase-iiiii-study-paclitaxelcarboplatin/?qd=65666353 A phase II/III Study of Paclitaxel/Carboplatin alone or Combined with either Trastuzumab and... New life-saving treatments for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma in clinical trial on A phase II/III Study of Paclitaxel/Carboplatin... https://pubmed.ncbi.nlm.nih.gov/39841861/ Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in... HER2 loss and decrease in HER2 expression are common in patients with MBC receiving treatment with T-DXd. Reevaluation of HER2 status following T-DXd treatment... epidermal growth factor https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-trastuzumab-pamirtecan-womb-cancer-fern-ec-01 Cancer Research UK | A trial looking at trastuzumab pamirtecan for womb cancer (Fern-EC-01) This trial is comparing trastuzumab pamirtecan with standard chemotherapy for womb cancer. cancer research uk https://pubmed.ncbi.nlm.nih.gov/18661530/?dopt=Abstract Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic... https://www.medlineplus.gov/druginfo/meds/a620048.html Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection: MedlinePlus Drug Information Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus pertuzumab trastuzumab hyaluronidase injection medlineplus https://pubmed.ncbi.nlm.nih.gov/22300778/?dopt=Abstract Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer In clinical practice, Tcardiotox is frequent in HER2-positive women with EBC and occurs in the first 3 months of therapy. Cardiac dysfunction is mild and... https://pubmed.ncbi.nlm.nih.gov/37751561/ Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive... Tucatinib combined with trastuzumab had clinically significant antitumor activity and was well tolerated in patients with previously treated HER2+ mBTC. epidermal growth factor https://boris-portal.unibe.ch/entities/publication/159f0fff-0e83-4c7a-ae34-43b84ca39076 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an... BACKGROUND Trastuzumab has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. The standard of care is 1 year... https://adisinsight.springer.com/trials/700057858?error=cookies_not_supported&code=08ae7530-4bd8-4c1d-a5c5-a9a448a98429 Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab... This study is investigating the efficacy and tolerability of early versus late lapatinib + capecitabine, initiated immediately after progression on trastuzumab clinical outcomes https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-lapatinib-trastuzumab-docetaxel-her-2-positive-breast-cancer-lapatax A trial looking at lapatinib, trastuzumab and chemotherapy before surgery for breast cancer... This trial looked at lapatinib, trastuzumab and chemotherapy before surgery for breast cancer.